These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28811232)

  • 1. CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients.
    Yang L; Zou S; Shu C; Song Y; Sun YK; Zhang W; Zhou A; Yuan X; Yang Y; Hu S
    Genomics Proteomics Bioinformatics; 2017 Aug; 15(4):255-262. PubMed ID: 28811232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
    Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
    Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
    Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
    Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
    Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
    Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
    Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
    Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
    Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
    Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.
    Kim KP; Jang G; Hong YS; Lim HS; Bae KS; Kim HS; Lee SS; Shin JG; Lee JL; Ryu MH; Chang HM; Kang YK; Kim TW
    Br J Cancer; 2011 Feb; 104(4):605-12. PubMed ID: 21326246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
    Kim MJ; Kong SY; Nam BH; Kim S; Park YI; Park SR
    Pharmacogenet Genomics; 2018 Jan; 28(1):23-30. PubMed ID: 29189588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
    Oh SY; Kwon HC; Jeong SH; Joo YT; Lee YJ; Cho Sh; Kang MH; Go SI; Lee GW; Kim Hg; Kang JH
    Invest New Drugs; 2012 Feb; 30(1):350-6. PubMed ID: 20706861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.
    Kim YW; Kim MJ; Ryu KW; Lim HS; Lee JH; Kong SY; Lee JS; Choi IJ; Kim CG; Lee JY; Cho SJ; Kook MC; Park YI; Kim SK; Park SR
    Gastric Cancer; 2016 Apr; 19(2):586-596. PubMed ID: 25851942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
    Jiang J; Zheng X; Xu X; Zhou Q; Yan H; Zhang X; Lu B; Wu C; Ju J
    PLoS One; 2011; 6(8):e23271. PubMed ID: 21876743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.
    Gao SG; Jia RN; Feng XS; Xie XH; Shan TY; Pan LX; Song NS; Wang YF; Ding KL; Wang LD
    World J Gastroenterol; 2011 Dec; 17(47):5221-6. PubMed ID: 22215948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Additional S-1 Chemotherapy to S-1 Plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection.
    Chen C; Tang CW; Huang SX; Shen CL
    Cancer Invest; 2022 Jan; 40(1):73-80. PubMed ID: 34595966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
    Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
    World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.